{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T20:29:38Z","timestamp":1793996978465,"version":"4.8.0"},"reference-count":23,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T00:00:00Z","timestamp":1778544000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinicalnutritionespen.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Nutrition ESPEN"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.clnesp.2026.103332","type":"journal-article","created":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T13:14:35Z","timestamp":1778764475000},"page":"103332","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Turning obesity into an iatrogenic disease?"],"prefix":"10.1016","volume":"74","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8143-9856","authenticated-orcid":false,"given":"Didier","family":"Quilliot","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"8","key":"10.1016\/j.clnesp.2026.103332_bib1","first-page":"560","article-title":"Off-label antiobesity treatment in patients without diabetes with GLP-1 agonists in clinical practice","volume":"47","author":"Sauer","year":"2015","journal-title":"Horm Metab Res"},{"key":"10.1016\/j.clnesp.2026.103332_bib2","unstructured":"https:\/\/www.medscape.com\/viewarticle\/real-world-study-finds-over-50-stop-glp-1s-within-1-year-2025a1000obm."},{"issue":"1","key":"10.1016\/j.clnesp.2026.103332_bib3","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2024.57349","article-title":"Discontinuation and reinitiation of dual-labeled GLP-1 receptor agonists among US adults with overweight or obesity","volume":"8","author":"Rodriguez","year":"2025","journal-title":"JAMA Netw Open"},{"issue":"9","key":"10.1016\/j.clnesp.2026.103332_bib4","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1002\/oby.24331","article-title":"Changes in weight and glycemic control following obesity treatment with semaglutide or tirzepatide by discontinuation status","volume":"33","author":"Gasoyan","year":"2025","journal-title":"Obesity"},{"issue":"11","key":"10.1016\/j.clnesp.2026.103332_bib5","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1056\/NEJMoa2032183","article-title":"Once-weekly semaglutide in adults with overweight or obesity","volume":"384","author":"Wilding","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clnesp.2026.103332_bib6","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2024.102624","article-title":"Once-weekly semaglutide versus placebo in adults with increased fracture risk: a randomised, double-blinded, two-centre, phase 2 trial","volume":"72","author":"Hansen","year":"2024","journal-title":"EClinicalMedicine"},{"key":"10.1016\/j.clnesp.2026.103332_bib7","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.clnu.2024.12.004","article-title":"Beyond fat: does semaglutide affect lean mass?","volume":"44","author":"Jamialahmadi","year":"2025","journal-title":"Clin Nutr"},{"issue":"11","key":"10.1016\/j.clnesp.2026.103332_bib8","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1016\/S2213-8587(25)00226-8","article-title":"Once-weekly semaglutide 7.2 mg in adults with obesity (STEP UP): a randomised, controlled, phase 3b trial","volume":"13","author":"Wharton","year":"2025","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"1","key":"10.1016\/j.clnesp.2026.103332_bib9","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1111\/dom.70141","article-title":"Impact of semaglutide on fat mass, lean mass and muscle function in patients with obesity: the SEMALEAN study","volume":"28","author":"Alissou","year":"2026","journal-title":"Diabetes Obes Metab"},{"issue":"3","key":"10.1016\/j.clnesp.2026.103332_bib10","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1038\/s41591-026-04204-0","article-title":"Bimagrumab plus semaglutide alone or in combination for the treatment of obesity: a randomized phase 2 trial","volume":"32","author":"Heymsfield","year":"2026","journal-title":"Nat Med"},{"issue":"8","key":"10.1016\/j.clnesp.2026.103332_bib11","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1111\/dom.14725","article-title":"Weight regain and cardiometabolic effects after withdrawal of semaglutide: the STEP 1 trial extension","volume":"24","author":"Wilding","year":"2022","journal-title":"Diabetes Obes Metab"},{"issue":"1","key":"10.1016\/j.clnesp.2026.103332_bib12","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1001\/jama.2023.24945","article-title":"Continued treatment with tirzepatide for maintenance of weight reduction in adults with obesity: the SURMOUNT-4 randomized clinical trial","volume":"331","author":"Aronne","year":"2024","journal-title":"JAMA"},{"issue":"11","key":"10.1016\/j.clnesp.2026.103332_bib13","doi-asserted-by":"crossref","DOI":"10.3390\/jcm14113791","article-title":"Weight regain after liraglutide, semaglutide or tirzepatide interruption: a narrative review of randomized studies","volume":"14","author":"Quarenghi","year":"2025","journal-title":"J Clin Med"},{"key":"10.1016\/j.clnesp.2026.103332_bib14","doi-asserted-by":"crossref","DOI":"10.1136\/bmj-2025-085304","article-title":"Weight regain after cessation of medication for weight management: systematic review and meta-analysis","volume":"392","author":"West","year":"2026","journal-title":"BMJ"},{"issue":"14","key":"10.1016\/j.clnesp.2026.103332_bib15","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.1001\/jama.2021.3224","article-title":"Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance in adults with overweight or obesity: the STEP 4 randomized clinical trial","volume":"325","author":"Rubino","year":"2021","journal-title":"JAMA"},{"issue":"9","key":"10.1016\/j.clnesp.2026.103332_bib16","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1016\/S2213-8587(24)00182-7","article-title":"Efficacy and safety of once-weekly semaglutide 2.4 mg versus placebo in people with obesity and prediabetes (STEP 10): a randomised, double-blinded, placebo-controlled, multicentre phase 3 trial","volume":"12","author":"McGowan","year":"2024","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"1","key":"10.1016\/j.clnesp.2026.103332_bib17","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1411892","article-title":"A randomized, controlled trial of 3.0 mg of liraglutide in weight management","volume":"373","author":"Pi-Sunyer","year":"2015","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.clnesp.2026.103332_bib18","doi-asserted-by":"crossref","DOI":"10.1111\/cob.12734","article-title":"Time to weight plateau with tirzepatide treatment in the SURMOUNT-1 and SURMOUNT-4 clinical trials","volume":"15","author":"Horn","year":"2025","journal-title":"Clin Obes"},{"issue":"1","key":"10.1016\/j.clnesp.2026.103332_bib19","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.mcna.2017.08.012","article-title":"Maintenance of lost weight and long-term management of obesity","volume":"102","author":"Hall","year":"2018","journal-title":"Med Clin North Am"},{"issue":"1","key":"10.1016\/j.clnesp.2026.103332_bib20","doi-asserted-by":"crossref","first-page":"66","DOI":"10.3945\/ajcn.111.014399","article-title":"Estimating changes in free-living energy intake and its confidence interval","volume":"94","author":"Hall","year":"2011","journal-title":"Am J Clin Nutr"},{"issue":"Suppl 1","key":"10.1016\/j.clnesp.2026.103332_bib21","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1111\/obr.12253","article-title":"How dieting makes the lean fatter: from a perspective of body composition autoregulation through adipostats and proteinstats awaiting discovery","volume":"16","author":"Dulloo","year":"2015","journal-title":"Obes Rev"},{"issue":"7","key":"10.1016\/j.clnesp.2026.103332_bib22","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1056\/NEJMoa2502081","article-title":"Coadministered cagrilintide and semaglutide in adults with overweight or obesity","volume":"393","author":"Garvey","year":"2025","journal-title":"N Engl J Med"},{"issue":"Suppl 1","key":"10.1016\/j.clnesp.2026.103332_bib23","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1111\/obr.12251","article-title":"Dieting and weight cycling as risk factors for cardiometabolic diseases: who is really at risk?","volume":"16","author":"Montani","year":"2015","journal-title":"Obes Rev"}],"container-title":["Clinical Nutrition ESPEN"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405457726004286?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405457726004286?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T21:27:06Z","timestamp":1783632426000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2405457726004286"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":23,"alternative-id":["S2405457726004286"],"URL":"https:\/\/doi.org\/10.1016\/j.clnesp.2026.103332","relation":{},"ISSN":["2405-4577"],"issn-type":[{"value":"2405-4577","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Turning obesity into an iatrogenic disease?","name":"articletitle","label":"Article Title"},{"value":"Clinical Nutrition ESPEN","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clnesp.2026.103332","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Ltd on behalf of European Society for Clinical Nutrition and Metabolism.","name":"copyright","label":"Copyright"}],"article-number":"103332"}}